Competition Law in the Pharmaceutical Sector

Hear directly from Paul Csiszár, Director “Basic Industries, Manufacturing and Agriculture”, DG Competition, European Commission on the current priorities in the sector and ask your burning questions during the Q&A.

Then join the enforcers’ roundtable to review developments in key jurisdictions including in Belgium, Czech Republic, Italy and the Netherlands.

Review the EU Vifor investigation and the issues at stake, whether the Commission’s approach is different to recent French cases and what advice companies should be considering in light of these cases.

Analyse where are we with Pfizer/ Flynn after the appeals as well as excessive pricing cases at national level, the challenges in assessing and enforcing theories of harm and what discounts and rebates are legitimate during this practical session. 

Gain an update on jurisdiction and approaches to killer acquisitions after Illumina/Grail and discuss whether there is increased scrutiny of mergers in the pharma sector including the aims of the multilateral (FTC, EU, UK) pharmaceutical merger task force.

Discuss industry cooperation and collaboration in light of the revised Horizontal Block Exemption Regulations including the R&D block exemption and consider what practical lessons can be learnt from recent cases. 

Join this interactive panel session for full update on significant recent cases including AG Opinion in Servier, their implications for patent filing strategies, patent pooling and the latest on reverse patent settlements.